Status:
COMPLETED
Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Lead Sponsor:
University of California, Los Angeles
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-54 years
Phase:
PHASE4
Brief Summary
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This appears to be responsible for their difficulties in social and occupational functioning. One particular cogn...
Detailed Description
Schizophrenia is a disorder of cognition. The cognitive deficits of schizophrenia are present at the onset of the disorder, prior to medication exposure, are persistent during periods of remission, an...
Eligibility Criteria
Inclusion
- adults age 18-54
- diagnosis of schizophrenia or schizoaffective disorder, or healthy with no personal or family history of mental illness
- able to provide informed consent
Exclusion
- history of significant head injury or other neurological illness
- active psychiatric illness requiring significant acute care
- significant intellectual impairment (e.g. standardized full-scale IQ \< 70)
- history of medical illness or treatment that either interferes with experimental measures (e.g. cerebrovascular disease, anemias, etc.) or is associated with significant increase in risk from modafinil treatment (e.g. cardiac disease)
- significant active substance abuse
- presence of ferromagnetic foreign body or prosthesis
- active pregnancy
- active treatment with medications that have drug interactions with modafinil
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00423943
Start Date
September 1 2005
End Date
December 1 2012
Last Update
September 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Los Angeles School of Medicine
Los Angeles, California, United States, 90095